Special Issue

Integrative and Preventive Biomarkers for Cardiometabolic Diseases

Message from the Guest Editors

Cardiometabolic diseases, including cardiovascular disease, type 2 diabetes, and metabolic syndrome, are among the leading causes of morbidity and mortality worldwide. Despite significant advances in diagnostics and treatment, a critical gap remains in translating biomarker discoveries into integrative and preventive healthcare solutions. This Special Issue will highlight cutting-edge research on biomarkers that facilitate early detection, risk assessment, and personalized prevention strategies.

We are inviting submissions that explore novel and established biomarkers, their clinical utility, and their integration into multi-disciplinary healthcare approaches. Topics of interest include, but are not limited to, the following:

- 1.Biomarkers for early risk prediction and disease progression monitoring;
- 2. The role of inflammation, oxidative stress, and metabolic dysregulation in cardiometabolic health;
- 3. Multi-omics approaches to biomarker discovery;
- 4.Al-driven biomarker identification and precision medicine applications;
- 5.Integration of biomarkers into pharmacological interventions;
- 6. Challenges in translating biomarker research into clinical practice.

Guest Editors

Prof. Dr. Tandi E. Matsha

- 1. Sefako Makgatho Health Sciences University, Ga Rankuwa 0208, South Africa
- 2. SAMRC/CPUT Cardiometabolic Health Research Unit, Department of Biomedical Sciences, Faculty of Health and Wellness Sciences, Cape Peninsula University of Technology, Bellville 7530, South Africa

Dr. Shanel Raghubeer

SAMRC/CPUT Cardiometabolic Health Research Unit, Department of Biomedical Sciences, Faculty of Health and Wellness Sciences, Cape Peninsula University of Technology, Bellville 7530, South Africa

Deadline for manuscript submissions

30 September 2025



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/232998

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).